Integral Health Asset Management’s Ventyx Biosciences VTYX Stock Holding History

Integral Health Asset Management’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-500,000	Closed	-$1.24M	–	95
2023 Q4	$1.24M	Buy	500,000 +70,000	+16%	+$665K	0.17%	69
2023 Q3	$14.9M	Buy	430,000 +80,000	+23%	+$2.77M	2.07%	17
2023 Q2	$11.5M	Buy	350,000 +60,000	+21%	+$2.07M	1.42%	29
2023 Q1	$9.71M	Buy	290,000 +80,000	+38%	+$3.11M	1.96%	22
2022 Q4	$6.89M	Buy	210,000 +110,000	+110%	+$3.26M	1.45%	28
2022 Q3	$3.49M	Buy	+100,000	New	+$2.21M	0.68%	51

Other funds holding VTYX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Integral Health Asset Management's VTYX Position: Q1 2024 in Review

Integral Health Asset Management sold out of Ventyx Biosciences (VTYX) in Q1 2024, closing a stake of 500,000 shares — an estimated $1.24M sold.

Integral Health Asset Management first reported a position in VTYX in Q3 2022 and held it in 6 quarters. The position peaked at $14.9M in Q3 2023. 126 funds tracked by Wall St. Rank hold VTYX as of Q1 2024.

Integral Health Asset Management reported no remaining Ventyx Biosciences position as of Q1 2024 after selling out during the quarter.
Integral Health Asset Management sold 500,000 Ventyx Biosciences shares in Q1 2024, an estimated $1.24M.
Integral Health Asset Management first reported a position in Ventyx Biosciences in Q3 2022 and held it in 6 quarters.
Integral Health Asset Management's Ventyx Biosciences position peaked at $14.9M in Q3 2023.
126 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2024.

Based on Integral Health Asset Management's 13F filing for Q1 2024, filed 15 May 2024.